KRAS and cancer: LY3962673 is another non-covalent KRAS G12D inhibitor with high affinity for KRAS G12D-GDP and demonstrated robust antitumor activity in cancer cell lines and multiple KRAS-G12D-mutant patient-derived xenograft (PDX) models [83].